Meanwhile, in lung cancer, the majority of reports associate mutant KRAS with increased PD-L1 expression (Figure 2) [43,44,45,46,47] and improved clinical response to anti-PD-1 therapy [44,45]. Here, PDCD1 is linked to lung carcinoma.